Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Mycopathologia ; 175(3-4): 361-3, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23526375

RESUMO

Data guiding management of pulmonary mycetomas are based on uncontrolled trials and case reports. Surgical resection represents a definitive treatment associated with high mortality and sometimes not feasible due to clinical conditions. We report a case of an immunocompetent patient with multiple pulmonary mycetomas, suggestive for probable chronic aspergillosis, in which surgery was contraindicated. The patient experienced a good response to long-term oral voriconazole therapy with remarkable clinical and radiological improvement at three-month follow-up. In cases of probable chronic aspergillomas, when surgery is contraindicated, long-term antifungal therapy with voriconazole seems to be a valid alternative option.


Assuntos
Antifúngicos/administração & dosagem , Micetoma/diagnóstico , Micetoma/tratamento farmacológico , Aspergilose Pulmonar/diagnóstico , Aspergilose Pulmonar/tratamento farmacológico , Pirimidinas/administração & dosagem , Triazóis/administração & dosagem , Idoso , Humanos , Pulmão/diagnóstico por imagem , Pulmão/patologia , Masculino , Micetoma/patologia , Aspergilose Pulmonar/patologia , Radiografia , Resultado do Tratamento , Voriconazol
2.
Infection ; 40(5): 527-35, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22711599

RESUMO

BACKGROUND: The characteristics of patients with infective endocarditis (IE) vary significantly by region of the world. The aim of this study was to evaluate the contemporary epidemiology, characteristics, and outcome of IE in a large, nationwide cohort of Italian patients. METHODS: We conducted a prospective, observational study at 24 medical centers in Italy, including all the consecutive patients with a definite or possible diagnosis of IE (modified Duke criteria) admitted from January 2004 through December 2009. A number of clinical variables were collected through an electronic case report form and analyzed to comprehensively delineate the features of IE. We report the data on patients with definite IE. RESULTS: A total of 1,082 patients with definite IE were included. Of these, 753 (69.6%) patients had infection on a native valve, 277 (25.6%) on a prosthetic valve, and 52 (4.8%) on an implantable electronic device. Overall, community-acquired (69.2%) was more common than nosocomial (6.2%) or non-nosocomial (24.6%) health care-associated IE. Staphylococcus aureus was the most common pathogen (22.0%). In-hospital mortality was 15.1%. From the multivariate analysis, congestive heart failure (CHF), stroke, prosthetic valve infection, S. aureus, and health care-associated acquisition were independently associated with increased in-hospital mortality, while surgery was associated with decreased mortality. CONCLUSIONS: The current mortality of IE remains high, and is mainly due to its complications, such as CHF and stroke.


Assuntos
Endocardite Bacteriana/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Análise de Variância , Feminino , Humanos , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Razão de Chances , Estudos Prospectivos , Fatores de Risco , Resultado do Tratamento , Adulto Jovem
3.
Chemotherapy ; 57(5): 426-33, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22122863

RESUMO

BACKGROUND: In 2004-2008, the epidemiological and clinical Infective Endocarditis Study Group (SEI) evaluated 852 cases of infective endocarditis. Staphylococcus aureus was the main involved pathogen (24.5%) and Enterococcus faecalis etiology was described in 11% of the cases. The aim of this study was to evaluate the in vitro activity of 12 antibiotics alone and in association against 27 strains of E. faecalis isolated from blood cultures of patients with infective endocarditis. RESULTS: The results showed high in vitro activity of tigecycline, daptomycin and linezolid. A high synergistic effect was obtained with the association ceftriaxone-fosfomycin [fractional inhibitory concentration (FIC)(50) = 0.34, FIC(90) = 0.78]. Furthermore, ceftriaxone plus ampicillin presented additive results (FIC(50) = 0.66, FIC(90) = 1.00), and ceftriaxone plus fosfomycin and ceftriaxone plus ampicillin were significantly more active in vitro than each drug alone. The efficacy of ceftriaxone plus fosfomycin was confirmed by the association testing using the broth dilution technique. CONCLUSION: Fosfomycin seems particularly significant and its association with ceftriaxone could be considered as a useful therapeutic option in medical treatment of E. faecalis infective endocarditis.


Assuntos
Antibacterianos/farmacologia , Ceftriaxona/farmacologia , Endocardite/microbiologia , Enterococcus faecalis/efeitos dos fármacos , Fosfomicina/farmacologia , Infecções por Bactérias Gram-Positivas/microbiologia , Animais , Sinergismo Farmacológico , Quimioterapia Combinada , Enterococcus faecalis/isolamento & purificação , Humanos , Itália , Testes de Sensibilidade Microbiana , Ovinos
4.
Int J STD AIDS ; 19(1): 65-6, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18275654

RESUMO

The incidence of syphilis has increased substantially over the past years, particularly in men who have sex with men. The clinical manifestations of syphilis are variable and liver involvement is uncommon, but may occur at any stage of the disease. We report a case of early syphilitic hepatitis (ESH) in an immunocompetent patient referring multiple bisexual exposures, who presented at admission with jaundice, tiredness, an ulcerated genital lesion and an increase of liver aminotransferases. During his hospital stay, he developed a skin rash, and serology for syphilis was found positive. Our case report strengthens the need to take into consideration the diagnosis of ESH in all patients with unexplained liver enzyme increase and epidemiological data of unsafe sexual exposures. Indeed, an early recognition of the clinical manifestations of syphilis can lead to a prompt treatment, and allows the prevention of the transmission of this disease to other individuals.


Assuntos
Hepatite , Sífilis/complicações , Adulto , Antibacterianos/uso terapêutico , Humanos , Testes de Função Hepática , Masculino , Comportamento Sexual , Sorodiagnóstico da Sífilis
6.
Curr HIV Res ; 9(4): 270-5, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21631426

RESUMO

BACKGROUND: Kaposi's sarcoma is commonly described in HIV/AIDS patients but usually manifests as overt skin lesions or visceral involvement. Bone involvement, particularly vertebral, is uncommon, especially when there is no adjacent cutaneous lesion but a small number of cases have been reported. Unlike many other diseases associated with HIV, Kaposi's sarcoma can occur despite a normal CD4 count. CASE PRESENTATION: A 44 year-old HIV positive Nigerian man presented with a 20 day history of severe, worsening lumbar back pain, nearly three years after an earlier diagnosis of a single cutaneous lesion consistent with Kaposi's sarcoma, for which he received chemo-radiotherapy. Despite varying previous compliance with his anti-retroviral therapy, he was thought to be taking his medications at time of presentation and his CD4 count was 408 cells/mm(3). No other organ involvement was found but a pathological fracture was seen on magnetic resonance imaging affecting L1 vertebra. A CT-guided needle aspiration biopsy was performed and a histological diagnosis subsequently confirmed Kaposi's sarcoma. The patient was treated with further courses of radiotherapy but had little clinical improvement. Indeed, a follow-up MRI four months later showed new involvement of a further four vertebrae, fortunately in the absence of progressive focal neurology. CONCLUSION: Vertebral Kaposi's sarcoma is a rare diagnosis but can be accurately diagnosed with CT or MRI imaging in conjunction with a histological diagnosis. An immunosuppressed patient presenting with bone pain should be thoroughly investigated for Kaposi's sarcoma as modern chemotherapeutic agents alongside anti-retroviral therapy may delay or prevent further devastating complications such as spinal cord compression.


Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Vértebras Lombares , Sarcoma de Kaposi/secundário , Neoplasias Cutâneas , Fraturas da Coluna Vertebral/etiologia , Neoplasias da Coluna Vertebral/secundário , Adulto , Fraturas Espontâneas/etiologia , Humanos , Perna (Membro) , Vértebras Lombares/lesões , Imageamento por Ressonância Magnética , Masculino , Sarcoma de Kaposi/radioterapia , Neoplasias da Coluna Vertebral/radioterapia , Resultado do Tratamento
8.
Support Care Cancer ; 8(6): 504-5, 2000 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11094997

RESUMO

A case of Saccharomyces fungemia in an 8-month-old baby affected by acute myeloid leukemia while receiving intensive chemotherapy is reported. The patient was receiving prophylaxis treatment with Saccharomyces boulardii capsules (Codex) to prevent diarrhea, which is commonly associated with this type of chemotherapy. Fever spiked just the day after ending the chemotherapy course, and a strain of Saccharomyces cerevisiae was isolated from blood culture although the patient was also receiving antifungal prophylaxis with fluconazole. The patient recovered, though still neutropenic, with amphotericin-B and removal of the central venous catheter. The common biochemical characteristics make it difficult to differentiate between the strain of Saccharomyces cerevisiae and that of Saccharomyces boulardii with routine methods. In other cases, authors demonstrated an identity between the two strains with a more detailed analysis. These reports raise concern about the potential side effects of such biotherapeutic agents.


Assuntos
Antifúngicos/efeitos adversos , Fungemia/etiologia , Hospedeiro Imunocomprometido , Leucemia Mieloide/imunologia , Neutropenia/imunologia , Saccharomyces cerevisiae/isolamento & purificação , Fermento Seco/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Cisplatino/efeitos adversos , Diarreia/induzido quimicamente , Diarreia/prevenção & controle , Etoposídeo/efeitos adversos , Fungemia/diagnóstico , Humanos , Ifosfamida/efeitos adversos , Lactente , Leucemia Mieloide/complicações , Leucemia Mieloide/tratamento farmacológico , Saccharomyces cerevisiae/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA